Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol

Journal of Medicinal Chemistry

Volumn 51, Issue 19, 2008, Pages 6095-6109

  Paul, Noel M ^a   Taylor, Michelle ^b   Kumar, Rakesh ^b   Deschamps, Jeffrey R ^c   Luedtke, Robert R ^b   Newman, Amy Hauck ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c NAVAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINYL]METHYLINDOLE; BENZOFURAN DERIVATIVE; BICYCLO COMPOUND; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; ENDO 8 (1H INDOL 3 YLMETHYL) 3 (3,4 DICHLOROPHENYL) 8 AZABICYCLO[3.2.1]OCTAN 3 OL; ENDO 8 (1H INDOL 3 YLMETHYL) 3 (4 CHLOROPHENY) 8 AZABICYCLO[3.2.1]OCTAN 3 OL; ENDO 8 (BENZOFUR 3 YLMETHYL) 3 (3,4 DICHLOROPHENYL) 8 AZABICYCLO[3.2.1]OCTAN 3 OL; ENDO 8 (BENZOFUR 3 YLMETHYL) 3 (4 FLUOROPHENYL) 8 AZABICYCLO[3.2.1]OCTAN 3 OL; L 741626; LIGAND; PIPERIDINE; PIPERIDINE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; RECEPTOR SUBTYPE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CHEMICAL MODIFICATION; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PHARMACOPHORE; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AZABICYCLO COMPOUNDS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, DOPAMINE D2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53549114257     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800532x     Document Type: Article

References (56)

1. (a) Meyer, J. M. Antipsychotic safety and efficacy concerns. J. Clin. Psychiatry 2007, 68, 20-26.
2. (b) Nikam, S. S.; Awasthi, A. K. Evolution of schizophrenia drugs: a focus on dopaminergic systems. Curr. Opin. Invest. Drugs 2008, 9 (1), 37-46.
3. Sokoloff, P.; Giros, B.; Martres, M.-P.; Bouthenet, M.-L.; Schwartz, J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347 (6289), 146-151.
4. Martinez, D.; Broft, A.; Foltin, R. W.; Slifstein, M.; Hwang, D.-R.; Huang, Y.; Perez, A.; Frankel, W. G.; Cooper, T.; Kleber, H. D.; Fischman, M. W.; Laruelle, M. Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology 2004, 29, 1190-1202.
5. (a) Volkow, N. D.; Fowler, J. S.; Wang, G. J. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J. Psychopharmacol. 1999, 13 (4), 337-345.
6. (b) Volkow, N. D.; Wang, G.-J.; Fowler, J. S.; Logan, J.; Gatley, S. J.; Gifford, A.; Hitzemann, R.; Ding, Y.-S.; Pappas, N. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am. J. Psychiatry 1999, 156 (9), 1440-1443.
7. (c) Volkow, N. D.; Fowler, J. S.; Wang, G.-J.; Swanson, J. M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry 2004, 9 (6), 557-569.
8. (d) Volkow, N. D.; Fowler, J. S.; Wang, G. J.; Swanson, J. M.; Telang, F. Dopamine in drug abuse and addiction. Results of imaging studies and treatment implications. Arch. Neurol. 2007, 64 (11), 1575-1579.
9. Nader, M. A.; Morgan, D.; Gage, H. D.; Nader, S. H.; Calhoun, T. L.; Buchheimer, N.; Ehrenkaufer, R.; Mach, R. H. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat. Neurosci. 2006, 9 (8), 1050-1056.
10. Thanos, P. K.; Katana, J. M.; Ashby, C. R.; Michaelides, M.; Gardner, E. L.; Heidbreder, C. A.; Volkow, N. D. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol., Biochem. Behav. 2005, 81 (1), 190-197.
11. Gyertyan, I.; Kiss, B.; Gal, K.; Laszlovszky, I.; Horvath, A.; Gemesi, L. I.; Saghy, K.; Pasztor, G.; Zajer, M.; Kapas, M.; Csongor, E. A.; Domany, G.; Tihanyi, K.; Szombathelyi, Z. Effects of RGH-237 [N-{4-[4-(3- aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzami de], an orally active, selective dopamine D-3 receptor partial agonist in animal models of cocaine abuse. J. Pharmacol. Exp. Ther. 2007, 320 (3), 1268-1278.
12. Le Foll, B.; Goldberg, S. R.; Sokoloff, P. Dopamine D-3 receptor ligands for the treatment of tobacco dependence. Expert Opin. Invest. Drugs 2007, 16 (1), 45-57.
13. Martelle, J. L.; Claytor, R.; Ross, J. T.; Reboussin, B. A.; Newman, A. H.; Nader, M. A. Effects of two novel D-3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2- carboxa mide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl) butyl)-4-(pyridin-2-yl)benza mide], on the reinforeing and discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 321 (2), 573-582.
14. Preti, A. New developments in the pharmacotherapy of cocaine abuse. Addict. Biol. 2007, 12 (2), 133-151.
15. Xi, Z. X.; Gardner, E. L. Pharmacological actions of NGB 2904, a selective dopamine D-3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev. 2007, 13 (2), 240-259.
16. Newman, A. H.; Grundt, P.; Nader, M. A. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem. 2005, 48 (11), 3663-3679.
17. Heidbreder, C. A.; Gardner, E. L.; Xi, Z.-X.; Thanos, P. K.; Mugnaini, M.; Hagan, J. J.; Ashby, J. C. R. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res. Rev. 2005, 49 (1), 77-105.
18. (a) Millan, M. J.; la Cour, C. M.; Novi, F.; Maggio, R.; Audinot, V.; Newman-Tancredi, A.; Cussac, D.; Pasteau, V.; Boutin, J.-A.; Dubuffet, T.; Lavielle, G. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b- tetrahydro 1-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J. Pharmacol. Exp. Ther. 2008, 324 (2), 587-599.
19. (b) Millan, M. J.; Svenningsson, P.; Ashby, C. R., Jr.; Hill, M.; Egeland, M.; Dekeyne, A.; Brocco, M.; Di Cara, B.; Lejeune, F.; Thomasson, N.; Munoz, C.; Mocaer, E.; Crossman, A.; Cistarelli, L.; Girardon, S.; Iob, L.; Veiga, S.; Gobert, A. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1, 3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl] phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J. Pharmacol. Exp. Ther. 2008, 324 (2), 600-611.
20. (c) Millan, M. J.; Loiseau, F.; Dekeyne, A.; Gobert, A.; Flik, G.; Cremers, T. I.; Rivet, J.-M.; Sicard, D.; Billiras, R.; Brocco, M. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J. Pharmacol. Exp. Ther. 2008, 324 (3), 1212-1226.
21. Boulay, D.; Depoortere, R.; Oblin, A.; Sanger, D. J.; Schoemaker, H.; Perrault, G. Haloperidol-induced catalepsy is absent in dopamine D2, but maintained in dopamine D3 receptor knock-out mice. Eur. J. Pharmacol. 2000, 391 (1-2), 63-73.
22. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discovery 2004, 3 (4), 353-359.
23. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48 (21), 6523-6543.
24. Gray, J. A.; Roth, B. L. Developing selectively nonselective drugs for treating CNS disorders. Drug Discovery Today: Ther. Strategies 2006, 3 (4), 413-419.
25. Van der Schyf, C. J.; Geldenhuys, W. J.; Youdim, M. B. H. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem. 2006, 99 (4), 1033-1048.
26. Schlyer, S.; Horuk, R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discovery Today 2006, 11 (11-12), 481-493.
27. Yocca, F.; Altar, C. A. Partial agonism of dopamine, serotonin and opiate receptors for psychiatry. Drug Discovers Today: Ther. Strategies 2006, 3 (4), 429-435.
28. Civelli, O.; Bunzow, J. R.; Grandy, D. K. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 1993, 33 (1), 281-307.
29. Agai-Csongor, E.; Nogradi, K.; Galambos, J.; Vago, I.; Bielik, A.; Magdo, I.; Ignacz-Szendrei, G.; Keseru, G. M.; Greiner, I.; Laszlovszky, I.; Schmidt, B. K. E.; Saghy, J. L. K.; Gyertyan, I.; Zajer-Balazs, M.; Gemesi, L.; Domany, G. Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile. Bioorg. Med. Chem. Lett. 2007, 17 (19), 5340-5344.
30. Cuisiat, S.; Bourdiol, N.; Lacharme, V.; Newman-Tancredi, A.; Colpaert, F.; Vacher, B. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. J. Med. Chem. 2007, 50 (4), 865-876.
31. Garzya, V.; Forbes, I. T.; Gribble, A. D.; Hadley, M. S.; Lightfoot, A. P.; Payne, A. H.; Smith, A. B.; Douglas, S. E.; Cooper, D. G.; Stansfield, I. G.; Meeson, M.; Dodds, E. E.; Jones, D. N. C.; Wood, M.; Reavill, C.; Scorer, C. A.; Worby, A.; Riley, G.; Eddershaw, P.; Ioannou, C.; Donati, D.; Hagan, J. J.; Ratti, E. A. Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg. Med. Chem. Lett. 2007, 17 (2), 400-405.
32. Kulagowski, J. J.; Broughton, H. B.; Curtis, N. R.; Mawer, I. M.; Ridgill, M. P.; Baker, R.; Emms, F.; Freedman, S. B.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C. I.; Leeson, P. D. 3-[[4-(4-Chlorophenyl)piperazin-1-yl] methyl]-1H-pyrrolo[2,3-b]pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J. Med. Chem. 1996, 39 (10), 1941-1942.
33. Grundt, P.; Husband, S. L. J.; Luedtke, R. R.; Taylor, M.; Newman, A. H. Analogues of the dopamine D2 receptor antagonist L741,626: binding, function, and SAR. Bioorg. Med. Chem. Lett. 2007, 17 (3), 745-749.
34. Vangveravong, S.; McElveen, E.; Taylor, M.; Xu, J.; Tu, Z.; Luedtke, R. R.; Mach, R. H. Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorg. Med. Chem. 2006, 14 (3), 815-825.
35. (a) Sikazwe, D. M. N.; Li, S.; Lyles-Eggleston, M.; Ablordeppey, S. Y. The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg. Med. Chem. Lett. 2003, 13 (21), 3779-3782.
36. (b) Lyles-Eggleston, M.; Altundas, R.; Xia, J.; Sikazwe, D. M. N.; Fan, P.; Yang, Q.; Li, S.; Zhang, W.; Zhu, X.; Schmidt, A. W.; Vanase-Frawley, M.; Shrihkande, A.; Villalobos, A.; Borne, R. F.; Ablordeppey, S. Y. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species. J. Med. Chem. 2004, 47 (3), 497-508.
37. (c) Sikazwe, D. M. N.; Li, S.; Mardenborough, L.; Cody, V.; Roth, B. L.; Ablordeppey, S. Y. Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors. Bioorg. Med. Chem. Lett. 2004, 14 (23), 5739-5742.
38. Robarge, M. J.; Husbands, S. M.; Kieltyka, A.; Brodbeck, R.; Thurkauf, A.; Newman, A. H. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl] alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype. J. Med. Chem. 2001, 44 (19), 3175-3186.
39. Newman, A. H.; Cao, J.; Bennett, C. J.; Robarge, M. J.; Freeman, R. A.; Luedtke, R. R. N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13 (13), 2179-2183.
40. Grundt, P.; Carlson, E. E.; Cao, J.; Bennett, C. J.; McElveen, E.; Taylor, M.; Luedtke, R. R.; Newman, A. H. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl} arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J. Med. Chem. 2005, 48 (3), 839-848.
41. Boeckler, F.; Gmeiner, P. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. Pharmacol. Ther. 2006, 112 (1), 281-333.
42. Grundt, P.; Prevatt, K. M.; Cao, J.; Taylor, M.; Floresca, C. Z.; Choi, J. K.; Jenkins, B. G.; Luedtke, R. R.; Newman, A. H. Heterocyclic Analogues of N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)aryl-carboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J. Med. Chem. 2007, 50 (17), 4135-4146.
43. Nielek, S.; Lesiak, T. Chemistry of thiazole. 1. Synthesis and properties of 2,3,5,6-tetrahydro-6-(3-methyl-benzofuran-2-yl)imidazo[2,1-b] thiazole. Chem. Ber./Recl. 1982, 115 (3), 1247-1251.
44. Zaidlewicz, M.; Chechlowska, A.; Prewysz-Kwinto, A.; Wojtczak, A. Enantioselective synthesis of 2-and 3-benzofuryl beta-amino alcohols. Heterocycles 2001, 55 (3), 569-577.
45. Shafiee, A.; Mohamadpour, M. Synthesis of 3-formylbenzo[b]furan and 1-methyl-3,4-dihydrobenzo[b]-furo[2,3-c]pyridine (1). J. Heterocycl. Chem. 1978, 15 (3), 481-483.
46. Grunewald, G. L.; Sall, D. J.; Monn, J. A. Conformationally defined adrenergic agents. 13. Conformational and steric aspects of the inhibition of phenylethanolamine N-methyltransferase by benzylamines. J. Med. Chem. 1988, 31 (2), 433-444.
47. Berdini, V.; Cesta, M. C.; Curti, R.; D'Anniballe, G.; Bello, N. D.; Nano, G.; Nicolini, L.; Topai, A.; Allegretti, M. A modified palladium catalysed reductive amination procedure. Tetrahedron 2002, 58 (28), 5669-5674.
48. Cope, A. C.; D'Addieco, A. A. Cyclic polyolefins. XVI. Phenylcycloheptatriene and phenylcycloöctatriene. J. Am. Chem. Soc. 1951, 73 (7), 3419-3424.
49. Gilbert, A. M.; Stack, G. P.; Nilakantan, R.; Kodah, J.; Tran, M.; Scerni, R.; Shi, X.; Smith, D. L.; Andree, T. H. Modulation of selective serotonin reuptake inhibitor and 5-HT1A antagonist activity in 8-aza-bicyclo[3.2.1]octane derivatives of 2,3-dihydro-1,4-benzodioxane. Bioorg. Med. Chem. Lett. 2004, 14 (2), 515-518.
50. Rawal, V. H.; Jones, R. J.; Cava, M. P. Photocyclization strategy for the synthesis of antitumor agent CC-1065: synthesis of dideoxy PDE-I and PDE-II. Synthesis of thiophene and furan analogs of dideoxy PDE-I and PDE-II. J. Org. Chem. 1987, 52 (1), 19-28.
51. Snyder, H. R.; Thompson, C. B.; Hinman, R. L. The synthesis of an indazole analog of DL-tryptophan. J. Am. Chem. Soc. 1952, 74 (8), 2009-2012.
52. Zou, M. F.; Kopajtic, T.; Katz, J. L.; Wirtz, S.; Justice, J. B.; Newman, A. H. Novel tropane-based irreversible ligands for the dopamine transporter. J. Med. Chem. 2001, 44 (25), 4453-4461.
53. GC/MS runs of the indolylmethyl and indazolylmethyl compounds 31-40 are inconclusive because of decomposition of the 8-arylmethyl linkage in the gas chromatograph, though dealkylated products are observed.
54. Alignment of 31 to the N(2)-C(10)-C(11)-C(12)-C(13)-C(14) atoms of 1 was produced using Sybyl 7.3 by Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144.
55. Javitch, J. A. Probing structure of neurotransmitter transporters by substituted-cysteine accessibility method. Neurotransm. Transp. 1998, 296, 331-346.
56. Ballesteros, J. A.; Shi, L.; Javitch, J. A. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001, 60 (1), 1-19.